[New approaches to the treatment of patients with idiopathic mitral valve prolapse].
OBJECTIVE
To assess efficiency of magnerot, magnesium orotate, in patients with idiopathic mitral prolapse (IMP).


METHODS
84 patients with IMP were randomized to the study group (43 patients) and control group (41 patients). Patients of the study group received magnerot tablets (Germany) containing 500 mg of magnesium orotate (daily dose 3000 mg) for 6 months. The examination performed before the treatment and 6 months after it included: modified clinical and phenotypic records, echocardiography, 24-h ECG and AP monitoring, spectral analysis of cardiac rhythm variability, evaluation of quality of life according to Visual Analog Scale and Disability Scale and of treatment results according to Clinical Global Impression scales, measurements of magnesium in the hair by plasmic nuclear emission spectrometry, histological and histochemical skin tests.


RESULTS
IMP patients appeared to suffer from magnesium deficiency which is responsible for many symptoms in mitral prolapse. 6-month therapy with magnerot completely or partially reduced the symptoms in more than half the patients. Positive changes were registered primarily in clinicofunctional manifestations. Morphological changes in the skin correlating with the disease severity alleviated.


CONCLUSIONS
Good objective and subjective response to magnerot 6-month therapy (3000 mg/day) is demonstrated.
Martynov
A I
AI
Stepura
O B
OB
Shekhter
A B
AB
Mel'nik
O O
OO
Pak
L S
LS
Ushakova
T I
TI
D000328:Adult; D000924:Anticholesteremic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003627:Data Interpretation, Statistical; D004452:Echocardiography; D015716:Electrocardiography, Ambulatory; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008275:Magnesium Deficiency / Q000150:complications / Q000188:drug therapy; D008297:Male; D008945:Mitral Valve Prolapse / Q000175:diagnosis / Q000188:drug therapy*; D009963:Orotic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013997:Time Factors
D000924:Anticholesteremic Agents; D009963:Orotic Acid; C104468:magnesium orotate